Trial Profile
A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms Ovarian-SPORE
- 11 Jan 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 11 Jan 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 23 Aug 2023 Planned End Date changed from 1 Nov 2023 to 1 Feb 2024.